Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDEAVOR: Exemestane for Ovulation Induction in PMOS/PCOS
NCT07706374Phase 1Recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of exemestane in polycystic ovary syndrome (PCOS) and infertility (4 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Number of participants with study-defined positive progesterone levels at Day 21. Started Oct 2026; status: recruiting.
02
Drugs
exemestane
03
Conditions
polycystic ovary syndrome (PCOS)infertility
Beyond the preview
Go deeper on NCT07706374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07706374.